The initiation of coverage by Deutsche Bank on Eli Lilly with a Hold rating suggests a neutral outlook for the stock. The price target of $535 indicates where the analyst believes the stock will trade in the near term. This could influence investor sentiment and potentially impact the stock's price, but the Hold rating suggests no significant movement is expected in the short term.